Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celtic Pharmaceutical and Neurobiological Technologies have initiated the second of two phase III pivotal trials of Xerecept for the treatment of peritumoral brain edema, or the swelling around brain cancers.
Subscribe to our email newsletter
This second study will compare the treatment of dexamethasone with Xerecept in patients already on low-dose steroid whose dose must be escalated to treat their symptoms.
In November 2005, NTI sold the worldwide exclusive rights to Xerecept to Celtic Pharma, and provides Celtic with contractual services surrounding the development of Xerecept.
“We feel that the existing treatment utilizing steroids provides an extra burden to this critically ill patient population,” said Paul Freiman, president and CEO of NTI. “We believe that Xerecept represents an alternative and hope to [give] these patients for a better quality of life.”